Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials
Dimitrios N. Sidiropoulos, … , Elana J. Fertig, Won Jin Ho
Dimitrios N. Sidiropoulos, … , Elana J. Fertig, Won Jin Ho
Published October 10, 2022
Citation Information: JCI Insight. 2022;7(19):e160398. https://doi.org/10.1172/jci.insight.160398.
View: Text | PDF
Technical Advance Immunology Oncology

Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials

  • Text
  • PDF
Abstract

Mass cytometry, or cytometry by TOF (CyTOF), provides a robust means of determining protein-level measurements of more than 40 markers simultaneously. While the functional states of immune cells occur along continuous phenotypic transitions, cytometric studies surveying cell phenotypes often rely on static metrics, such as discrete cell-type abundances, based on canonical markers and/or restrictive gating strategies. To overcome this limitation, we applied single-cell trajectory inference and nonnegative matrix factorization methods to CyTOF data to trace the dynamics of T cell states. In the setting of cancer immunotherapy, we showed that patient-specific summaries of continuous phenotypic shifts in T cells could be inferred from peripheral blood–derived CyTOF mass cytometry data. We further illustrated that transfer learning enabled these T cell continuous metrics to be used to estimate patient-specific cell states in new sample cohorts from a reference patient data set. Our work establishes the utility of continuous metrics for CyTOF analysis as tools for translational discovery.

Authors

Dimitrios N. Sidiropoulos, Genevieve L. Stein-O’Brien, Ludmila Danilova, Nicole E. Gross, Soren Charmsaz, Stephanie Xavier, James Leatherman, Hao Wang, Mark Yarchoan, Elizabeth M. Jaffee, Elana J. Fertig, Won Jin Ho

×

Figure 6

CyTOF integrated metrics can be projected across distinct patients, diseases, and immunological scenarios to annotate newly generated data sets and query proteomic outcomes-associated signatures.

Options: View larger image (or click on image) Download as PowerPoint
CyTOF integrated metrics can be projected across distinct patients, dise...
(A) CCR7 expression. NMF patterns from the PDAC CyTOF data set projected onto different cohorts of patients with HCC treated with nivolumab and patients with melanoma treated with ipilimumab. (B) Projected memory pattern weights in CD8+ T cells by response of patients with melanoma to ipilimumab, showing significantly increased means in responders at baseline. (C) Projected effector pattern weights in CD8+ T cells by patients with HCC disease etiology, showing significantly different means between treated and untreated viral status. Statistical significance was determined by group mean comparison t tests. Statistically significant P values adjusted for multiple comparisons (Holm-Bonferroni) are shown as follows: *P < 0.05; **P < 0.01.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts